N6‐Methyladenosine‐Modified CBX1 Regulates Nasopharyngeal Carcinoma Progression Through Heterochromatin Formation and STAT1 Activation
Source abstract
Abstract
Abstract Epitranscriptomic remodeling such as N6‐methyladenosine (m6A) modification plays a critical role in tumor development. However, little is known about the underlying mechanisms connecting m6A modification and nasopharyngeal carcinoma (NPC) progression. Here, CBX1 is identified, a histone methylation regulator, to be significantly upregulated with m6A hypomethylation in metastatic NPC tissues. The m6A‐modified CBX1 mRNA transcript is recognized and destabilized by the m6A reader YTHDF3. Furthermore, it is revealed that CBX1 promotes NPC cell migration, invasion, and proliferation through transcriptional repression of MAP7 via H3K9me3‐mediated heterochromatin formation. In addition to its oncogenic effect, CBX1 can facilitate immune evasion through IFN‐γ‐STAT1 signaling‐mediated PD‐L1 upregulation. Clinically, CBX1 serves as an independent predictor for unfavorable prognosis in NPC patients. The results reveal a crosstalk between epitranscriptomic and epigenetic regulation in NPC progression, and shed light on the functions of CBX1 in tumorigenesis and immunomodulation, which may provide an appealing therapeutic target in NPC.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA modifications and cancer · Epigenetics and DNA Methylation · MicroRNA in disease regulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Sun Yat‐sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy 651 Dongfeng Road East Guangzhou Guangdong 510060 China
Funding
National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province · Overseas Expertise Introduction Project for Discipline Innovation
References (74)
Show source-provided references
1. 10.1016/S0140-6736(19)30956-010.1016/S0140-6736(19)30956-0 ↗
2. 10.1200/JCO.20.0323710.1200/JCO.20.03237 ↗
3. 10.1038/s41571-021-00524-x10.1038/s41571-021-00524-x ↗
4. 10.1038/s41591-021-01482-810.1038/s41591-021-01482-8 ↗
5. 10.1186/s40425-019-0636-710.1186/s40425-019-0636-7 ↗
6. 10.1038/ng.300610.1038/ng.3006 ↗
7. 10.1073/pnas.160760611310.1073/pnas.1607606113 ↗
8. 10.1038/ncomms1412110.1038/ncomms14121 ↗
9. 10.21037/cco.2016.03.0610.21037/cco.2016.03.06 ↗
10. 10.1038/nrm176110.1038/nrm1761 ↗
11. 10.1038/ncomms466110.1038/ncomms4661 ↗
12. 10.1038/s12276-021-00657-010.1038/s12276-021-00657-0 ↗
13. 10.1038/nature1111210.1038/nature11112 ↗
14. 10.1158/2159-8290.CD-20-033110.1158/2159-8290.CD-20-0331 ↗
15. 10.1002/hep.3131310.1002/hep.31313 ↗
16. 10.1016/j.molcel.2019.04.02510.1016/j.molcel.2019.04.025 ↗
17. 10.1016/j.ccell.2020.02.00410.1016/j.ccell.2020.02.004 ↗
18. 10.1038/s41419-018-1224-310.1038/s41419-018-1224-3 ↗
19. 10.1038/s41418-021-00905-w10.1038/s41418-021-00905-w ↗
20. 10.3389/fonc.2020.0116610.3389/fonc.2020.01166 ↗
21. 10.1016/j.tig.2021.06.01410.1016/j.tig.2021.06.014 ↗
22. 10.1038/ncomms1405310.1038/ncomms14053 ↗
23. 10.1002/cac2.1210410.1002/cac2.12104 ↗
24. 10.1038/s41467-022-28158-210.1038/s41467-022-28158-2 ↗
25. Xu Y. · Nucleic Acids Res. · 2017 · 45 · D264
26. 10.1038/s41422-020-0374-x10.1038/s41422-020-0374-x ↗
27. 10.1038/cr.2017.1510.1038/cr.2017.15 ↗
28. 10.1038/cr.2017.1010.1038/cr.2017.10 ↗
29. 10.1016/j.molcel.2010.12.02110.1016/j.molcel.2010.12.021 ↗
30. 10.1038/nature72210.1038/nature722 ↗
31. 10.1038/nature0687510.1038/nature06875 ↗
32. 10.1038/nrm.2017.11910.1038/nrm.2017.119 ↗
33. 10.1038/nature0421910.1038/nature04219 ↗
34. 10.7554/eLife.2531710.7554/eLife.25317 ↗
35. 10.1016/j.molcel.2005.03.03110.1016/j.molcel.2005.03.031 ↗
36. 10.1038/s41467-018-03909-210.1038/s41467-018-03909-2 ↗
37. 10.1038/nature1091410.1038/nature10914 ↗
38. 10.1083/jcb.20180806510.1083/jcb.201808065 ↗
39. 10.1186/s12943-020-01292-510.1186/s12943-020-01292-5 ↗
40. 10.1126/science.aae047710.1126/science.aae0477 ↗
41. 10.1016/j.cmet.2020.10.02110.1016/j.cmet.2020.10.021 ↗
42. 10.1038/s41591-018-0217-110.1038/s41591-018-0217-1 ↗
43. 10.1038/nrg.2017.5710.1038/nrg.2017.57 ↗
44. 10.7150/thno.5496710.7150/thno.54967 ↗
45. 10.1038/s41593-017-0057-110.1038/s41593-017-0057-1 ↗
46. 10.1038/s41586-019-1016-710.1038/s41586-019-1016-7 ↗
47. 10.1093/nar/gkab54810.1093/nar/gkab548 ↗
48. 10.1101/gr.124818.11110.1101/gr.124818.111 ↗
49. 10.1038/ng127810.1038/ng1278 ↗
50. 10.1101/gr.539180610.1101/gr.5391806 ↗
51. 10.3390/cancers1403076310.3390/cancers14030763 ↗
52. 10.3892/ijo.2014.264610.3892/ijo.2014.2646 ↗
53. 10.1677/ERC-09-032110.1677/ERC-09-0321 ↗
54. 10.1002/2211-5463.1297110.1002/2211-5463.12971 ↗
55. 10.1016/j.tranon.2018.07.00210.1016/j.tranon.2018.07.002 ↗
56. 10.4161/epi.5.4.1168310.4161/epi.5.4.11683 ↗
57. 10.1186/1476-4598-12-9210.1186/1476-4598-12-92 ↗
58. 10.1530/ERC-18-047810.1530/ERC-18-0478 ↗
59. 10.7554/eLife.3637410.7554/eLife.36374 ↗
60. 10.1016/j.celrep.2019.01.08410.1016/j.celrep.2019.01.084 ↗
61. 10.1016/j.devcel.2020.01.02910.1016/j.devcel.2020.01.029 ↗
62. 10.3389/fonc.2021.68040210.3389/fonc.2021.680402 ↗
63. 10.1186/s12935-020-01446-x10.1186/s12935-020-01446-x ↗
64. 10.1186/s12935-020-1095-410.1186/s12935-020-1095-4 ↗
65. 10.1038/srep3454610.1038/srep34546 ↗
66. 10.3389/fonc.2021.65759510.3389/fonc.2021.657595 ↗
67. 10.3389/fonc.2020.58266710.3389/fonc.2020.582667 ↗
68. 10.1016/j.ccell.2020.02.00610.1016/j.ccell.2020.02.006 ↗
69. 10.1172/JCI12931710.1172/JCI129317 ↗
70. 10.1126/scitranslmed.abc391110.1126/scitranslmed.abc3911 ↗
71. 10.1016/j.immuni.2009.09.00210.1016/j.immuni.2009.09.002 ↗
72. 10.1096/fj.202100076RR10.1096/fj.202100076RR ↗
73. 10.1016/j.celrep.2018.02.00710.1016/j.celrep.2018.02.007 ↗
74. 10.3390/cells903055910.3390/cells9030559 ↗